Muller & Phipps (India) Ltd
Incorporated in 1917, Muller & Phipps (India) is engaged in marketing of over the counter medical preparation and home care products.
- Market Cap ₹ 12.6 Cr.
- Current Price ₹ 202
- High / Low ₹ 245 / 110
- Stock P/E 23.4
- Book Value ₹ -25.1
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 4.55% over past five years.
- Debtor days have increased from 67.8 to 86.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.99 | 4.26 | 3.67 | 4.50 | 3.47 | 3.40 | 3.13 | 3.74 | 3.61 | 3.97 | 3.67 | 3.91 | 4.29 | |
5.82 | 4.88 | 3.74 | 4.88 | 3.59 | 3.40 | 3.10 | 3.36 | 3.50 | 3.72 | 3.50 | 3.86 | 3.94 | |
Operating Profit | -0.83 | -0.62 | -0.07 | -0.38 | -0.12 | 0.00 | 0.03 | 0.38 | 0.11 | 0.25 | 0.17 | 0.05 | 0.35 |
OPM % | -16.63% | -14.55% | -1.91% | -8.44% | -3.46% | 0.00% | 0.96% | 10.16% | 3.05% | 6.30% | 4.63% | 1.28% | 8.16% |
0.19 | 0.13 | 0.18 | 1.14 | 0.38 | 0.30 | 0.18 | 0.08 | 0.38 | 1.61 | 0.38 | 0.26 | 0.27 | |
Interest | 0.32 | 0.55 | 0.31 | 0.31 | 0.31 | 0.24 | 0.24 | 0.21 | 0.14 | 0.12 | 0.10 | 0.09 | 0.08 |
Depreciation | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Profit before tax | -1.00 | -1.07 | -0.23 | 0.44 | -0.06 | 0.05 | -0.04 | 0.24 | 0.34 | 1.73 | 0.44 | 0.21 | 0.54 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 0.00% | 20.83% | 0.00% | 0.00% | 0.00% | 0.00% | |
-1.00 | -1.07 | -0.23 | 0.44 | -0.06 | 0.03 | -0.04 | 0.19 | 0.34 | 1.73 | 0.44 | 0.21 | 0.54 | |
EPS in Rs | -16.00 | -17.12 | -3.68 | 7.04 | -0.96 | 0.48 | -0.64 | 3.04 | 5.44 | 27.68 | 7.04 | 3.36 | 8.64 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -1% |
5 Years: | 5% |
3 Years: | 3% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 49% |
3 Years: | -15% |
TTM: | 170% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 44% |
3 Years: | 34% |
1 Year: | 32% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
Reserves | -4.66 | -5.73 | -5.96 | -5.52 | -5.58 | -5.52 | -5.55 | -5.35 | -5.00 | -3.30 | -2.87 | -2.66 | -2.20 |
1.78 | 1.77 | 1.91 | 1.90 | 1.89 | 1.89 | 1.89 | 2.04 | 1.90 | 1.62 | 1.34 | 1.06 | 3.02 | |
8.35 | 7.90 | 7.84 | 7.66 | 7.55 | 7.60 | 7.51 | 7.50 | 7.36 | 5.73 | 5.74 | 5.81 | 3.63 | |
Total Liabilities | 6.10 | 4.57 | 4.42 | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.84 | 5.08 |
0.15 | 0.12 | 0.09 | 0.08 | 0.07 | 0.04 | 0.05 | 0.04 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
5.94 | 4.44 | 4.32 | 4.58 | 4.41 | 4.55 | 4.42 | 4.77 | 4.81 | 4.60 | 4.77 | 4.78 | 5.02 | |
Total Assets | 6.10 | 4.57 | 4.42 | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.84 | 5.08 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.34 | 0.32 | -0.07 | 0.50 | 0.03 | 0.07 | 0.16 | -0.01 | 0.15 | 2.16 | 0.11 | 0.21 | |
0.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.02 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | |
-0.15 | -0.32 | 0.08 | -0.50 | -0.05 | -0.04 | -0.07 | 0.10 | -0.26 | -1.76 | -0.38 | -0.34 | |
Net Cash Flow | -0.10 | 0.00 | 0.01 | 0.00 | -0.01 | 0.04 | 0.07 | 0.09 | -0.14 | 0.39 | -0.27 | -0.13 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 35.11 | 33.42 | 31.83 | 51.10 | 50.49 | 59.04 | 40.81 | 40.01 | 30.33 | 45.05 | 71.61 | 86.82 |
Inventory Days | 12.22 | 13.04 | 4.03 | 3.13 | 2.04 | 8.44 | 13.42 | 16.17 | 34.30 | 26.55 | 45.03 | 36.08 |
Days Payable | 555.90 | 492.10 | 572.71 | 458.99 | 519.97 | 525.35 | 641.43 | 542.88 | 575.67 | 455.70 | 502.47 | 475.35 |
Cash Conversion Cycle | -508.57 | -445.65 | -536.85 | -404.76 | -467.44 | -457.86 | -587.20 | -486.70 | -511.04 | -384.10 | -385.83 | -352.46 |
Working Capital Days | -318.92 | -354.72 | -433.62 | -310.66 | -423.90 | -421.90 | -473.45 | -387.45 | -386.23 | -184.80 | -172.06 | -152.16 |
ROCE % |
Documents
Announcements
-
Compliance Certificate For The Year Ended 31-03-2024
24 Apr - Practicing Company Secretary certificate under Reg 40(9) of SEBI (LODR) Regulation, 2015 for the year ended 31-03-2024
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 12 Apr
- Compliance Certificate For The Period 01-04-2023 To 31-03-2024 12 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 31-03-2024, received from M/s Link Intime India Private Limited
- Closure of Trading Window 28 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1]
a) Cavisan - Medicated Dental Cream[2]
b) Cavifast - Medicated Dental Cream[3]
c) Cavisan - Gum Astringent[4]
d) Nixoderm[5]